November observance focuses on diabetes-related eye disease
Ophthalmology Times reports that Prevent Blindness has designated November as Diabetes-related Eye Disease Month. The 2026 observance draws attention to diabetic retinopathy (DR), an eye complication associated with diabetes, as well as diabetic macular edema (DME).
The publisher cites an estimate that 9.6 million people in the United States are living with diabetic retinopathy, including about 1.84 million people with vision-threatening diabetic retinopathy. It also reports that approximately one in three people with diabetes do not receive annual eye examinations.
For people with diabetes, families, and vision-loss community members, these figures underscore why eye-health discussions may be an important part of ongoing diabetes care. The article frames awareness month as an opportunity to address missed screening and to discuss changes in screening approaches and retinal treatments.
What the publisher describes
Rather than reporting a single new clinical trial or treatment announcement, the Ophthalmology Times item is presented as a frequently asked questions article. It says it covers three broad areas: gaps in eye screening, updates to clinical guidance, and recent trial findings involving diabetic retinopathy and diabetic macular edema.
The article also notes that artificial intelligence-based screening and newer therapies are reshaping care. However, the supplied publisher text does not name a particular AI system, provide performance data, identify updated guidelines, or describe individual therapies or trial results. It therefore does not establish whether any specific screening technology or treatment is appropriate, effective, safe, available, or beneficial for a particular person.
Why awareness and access are central themes
Diabetic retinopathy can affect the retina, the light-sensitive tissue at the back of the eye. DME refers to swelling involving the macula, the central retinal area used for detailed vision. The publisher’s emphasis on annual examinations points to a practical public-health concern: people may miss eye evaluations even when diabetes is known.
The reported estimate of 1.84 million people with vision-threatening disease also highlights that diabetic eye disease can reach more serious stages. Still, the publisher text does not explain how these estimates were calculated, which populations were included, or when the underlying data were collected. It cites references, but those references are not included in the supplied material.
Important limitations
This is an awareness-focused news item, not a peer-reviewed study report. The available text provides population estimates and describes topics the full FAQ intends to address, but it contains no detailed clinical evidence, study design, participant characteristics, outcomes, or follow-up information. Readers should not interpret the article as evidence for a specific treatment, screening schedule beyond the annual-exam statistic it reports, or expected visual outcome.
For community members seeking local education or support during Diabetes-related Eye Disease Month, the announcement may help prompt questions about diabetic eye disease, access to eye care, and the role of screening. The limited source material does not provide program contacts, eligibility details, or individualized care guidance.
Publisher source
Ophthalmology Times: FAQ: Diabetic eye disease awareness month 2026